Repligen Corporation · RGEN · Next earnings

Repligen Corporation reports Tuesday, Oct 27, 2026

RGEN reports before market open with consensus EPS at $0.46 and revenue at $206.7M. Last quarter: Repligen posts record Q3 revenue and raises 2026 guidance

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.46 Calendar consensus
Consensus revenue $206.7M Calendar consensus
Report date Oct 27, 2026 Tuesday, date estimated
Session Before market open 0 days away

Where RGEN left off: FY2026 Q3

Full report

Repligen posts record Q3 revenue and raises 2026 guidance

EPS surprise — Reported — vs $0.46
Revenue surprise — Reported — vs $206.7M
Stock move -2.2% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised 2026 guidance to an $848 million revenue midpoint and 12–13% organic growth, with operating margin near 16%.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Capital-equipment revenue could remain delayed if the market stays partially closed.
  • Cell-therapy approval timing could affect the expected BioLife upside.
  • Integration execution, inflation, and foreign-currency headwinds could pressure margins.

Questions analysts left open

  • BioLife integration timing and the magnitude of expected benefits.
  • Capital-equipment demand remains stronger in orders than in recognized revenue.
  • Filtration headwinds, on-shoring timing, and visibility into the order book.

Ask FN2 about RGEN next report

Transcript, numbers and history already loaded
What should I watch for in RGEN's next earnings report?How did RGEN guide last quarter, and is consensus above or below that?Give me the bull and bear case going into RGEN earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the RGEN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent RGEN quarters

All RGEN earnings
-2.2%FY2026 Q3+10.9%FY2026 Q2+6.3%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.